Aurobindo Pharma的美国设施开始生产,全球扩张和新产品推动增长,预计到26财政年度将达到20-21%的利润率。 Aurobindo Pharma's U.S. facility begins production, with global expansion and new products driving growth and a projected 20-21% margin by FY26.

Aurobindo Pharma的中国设施每季损失约100万美元,但预计甚至到2026财政年度后期也会破损,其口服固体食品厂的生产能力接近20亿单位,并得到了监管批准。 Aurobindo Pharma’s China facility is losing about $1 million per quarter but is expected to break even by late fiscal year 2026, with its oral-solid-dosage plant nearing 2 billion units in capacity and backed by regulatory approvals. 在印度,Pen-G生产量达到1 050公吨(Q2),产能为40-50%,如果执行最低进口价格,计划扩大到15 000公吨。 In India, Pen-G production reached 1,050 metric tons in Q2 at 40-50% capacity, with plans to expand to 15,000 MT if a minimum import price is implemented. 美国代顿设施已进入商业生产,从1月开始发射,预计从27财政年度获得收入。 The U.S. Dayton facility has entered commercial production, with launches starting in January and revenue expected from FY27. Pen-G的扩张、生物变异、生物CMO的进展和Lannett的收购将推动增长,该公司有信心在26财政年度达到20%-21%的差值目标。 Growth will be driven by Pen-G expansion, biosimilars, biologic CMO progress, and the Lannett acquisition, with the company confident in hitting a 20-21% margin target for FY26.